Neurocrine Biosciences (NBIX) Total Current Liabilities (2016 - 2021)
Historic Total Current Liabilities for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $225.9 million.
- Neurocrine Biosciences' Total Current Liabilities fell 6302.78% to $225.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $225.9 million, marking a year-over-year decrease of 6302.78%. This contributed to the annual value of $186.5 million for FY2020, which is 6700.87% down from last year.
- Per Neurocrine Biosciences' latest filing, its Total Current Liabilities stood at $225.9 million for Q3 2021, which was down 6302.78% from $212.9 million recorded in Q2 2021.
- In the past 5 years, Neurocrine Biosciences' Total Current Liabilities registered a high of $611.0 million during Q3 2020, and its lowest value of $23.6 million during Q1 2017.
- For the 5-year period, Neurocrine Biosciences' Total Current Liabilities averaged around $199.5 million, with its median value being $115.7 million (2019).
- In the last 5 years, Neurocrine Biosciences' Total Current Liabilities soared by 109661.26% in 2018 and then crashed by 7465.99% in 2019.
- Quarter analysis of 5 years shows Neurocrine Biosciences' Total Current Liabilities stood at $54.4 million in 2017, then skyrocketed by 62.12% to $88.2 million in 2018, then surged by 540.69% to $565.3 million in 2019, then crashed by 67.01% to $186.5 million in 2020, then grew by 21.13% to $225.9 million in 2021.
- Its Total Current Liabilities was $225.9 million in Q3 2021, compared to $212.9 million in Q2 2021 and $190.0 million in Q1 2021.